WM-3835
Based on 11 publication(s) in Google Scholar
WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.78%
- No. CAS: 2229025-70-9
- Fòrmula: C20H17FN2O4S
- Peso molecular:400.42
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Targeted Diversity Library
HY-L099
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) WM-3835
More- Nat Cell Biol. 2026 Mar 27. [Abstract]
- Sci Adv. 2023 Nov 15;9(46):eadf3980. [Abstract]
- Blood Cancer Discov. 2026 Apr 19.
- Cell Death Dis. 2023 Aug 4;14(8):498. [Abstract]
- Dev Cell. 2024 Aug 27:S1534-5807(24)00492-1. [Abstract]
- Cell Rep. 2025 May 30;44(6):115757. [Abstract]
- J Hypertens. 2025 May 1;43(5):827-840. [Abstract]
- bioRxiv. 2026 Jan 8:2026.01.08.697228. [Abstract]
- University of Wisconsin. 2025.
- Res Sq. 2025 Jun 24:rs.3.rs-6456987. [Abstract]
- bioRxiv. 2025 Apr 26:2025.04.23.650241. [Abstract]
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
WB
-
RT-PCR
-
Cell Proliferation/Viability Assay
Actividad biológica
|
HBO1 |
WM-3835 (1-25 uM; 24-96 hours) inhibits pOS-1 cell viability in a concentration-dependent manner[1].
WM-3835 (5 uM; 72 h) activates cell apoptosis and significantly increases TUNEL-positive nuclei in pOS-1 cells[1].
WM-3835 (5 μM; 24 hours) downregulates MYLK-HOXA9 mRNA expression in pOS-1 cells[1].
WM-3835 (1-25 uM) suppresses H4K12ac-H3K14ac in a dose-dependent manner. WM-3835 does not alter the expressions of HBO1 protein and total H3, H4 histones[1].
WM-3835 (5 μM) fails to induce apoptosis and reduction of viability in HBO1-KO pOS-1 cells, koHBO1-1 and koHBO1-2, HBO1-low human osteoblasts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary human OS (pOS-1) cells
-
Concentration:1, 5, 10, 25 uM
-
Incubation Time:24, 48, 72, 96 hours
-
Result:Inhibited pOS-1 cell viability in a concentration-dependent manner.
Exerted a significant anti-survival activity at least 48 h, displaying a time-dependent manner.
-
Cell Line:pOS-1 cells
-
Concentration:5 uM
-
Incubation Time:72 hours
-
Result:Activated cell apoptosis and significantly increases TUNEL-positive nuclei.
-
Cell Line:pOS-1 cells
-
Concentration:5 uM
-
Incubation Time:24 hours
-
Result:Downregulated MYLK-HOXA9 mRNA expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice (18-19 g, female) with pOS1 cells[1]
-
Dosage:10 mg/kg
-
Administration:IP; daily; for 21 days
-
Result:Potently inhibited pOS-1 xenograft growth.
Chemical Information
-
No. CAS 2229025-70-9
-
Appearance Solid
-
Peso molecular 400.42
-
Fòrmula C20H17FN2O4S
-
Color White to off-white
-
SMILES
O=C(C1=CC(C2=CC=CC=C2)=CC(C)=C1F)NNS(=O)(C3=CC=CC(O)=C3)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs. [Abstract]2026 Mar 27. PMID: 41896311 -
Sci Adv
2023 Nov 15;9(46):eadf3980. PMID: 37976354 -
-
Cell Death Dis
Histone acetylation by HBO1 (KAT7) activates Wnt/β-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia. [Abstract]2023 Aug 4;14(8):498. PMID: 37542030
WM-3835 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Aug 4;14(8):498. [Abstract]
Dose-effect curves of the inhibitory action of WM-3835 (0.1-100 μM) on listed cells in vitro for 96 h.The results showed that WM-3835 significantly inhibited the viability of B-ALL cell lines and primary cells derived from B-ALL patients in a concentration-dependent manner (Fig. A, B), but had no effect on the viability of normal human peripheral blood mononuclear cells (PBMCs) and HBO1 knockdown B-ALL cells (Fig. C, D).
WM-3835 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Aug 4;14(8):498. [Abstract]
Cell cycle progression was detected by FACS (left) and statistically analyzed (right) after NALM-6 and REH cells were treated with 0.1% DMSO or 2 μM WM-3835 for 96 hours.
-
Dev Cell
Dual function of PHF16 in reinstating homeostasis of murine intestinal epithelium after crypt regeneration. [Abstract]2024 Aug 27:S1534-5807(24)00492-1. PMID: 39232563 -
Cell Rep
2025 May 30;44(6):115757. PMID: 40450685
WM-3835 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 May 30;44(6):115757. [Abstract]
Western blots showing H3K14Ac levels in mES cells treated with KAT7 inhibitor (WM-3835, 10-100 μM; 3-12 h) for gradient duration and concentration.
-
J Hypertens
KAT7 contributes to ponatinib-induced hypertension by promoting endothelial senescence and inflammatory responses through activating NF-κB signaling pathway. [Abstract]2025 May 1;43(5):827-840. PMID: 40084466
WM-3835 purchased from MedChemExpress. Usage Cited in: J Hypertens. 2025 May 1;43(5):827-840. [Abstract]
Cell viability was measured by CCK-8 in MAECs under control condition or treated with 100 nM ponatinib in the absence or in the presence of 100 nM WM-3835 for 24 h. The data are means ± SEM, n = 7 per group. ∗P < 0.05 versus control; #P < 0.05 versus ponatinib.
WM-3835 purchased from MedChemExpress. Usage Cited in: J Hypertens. 2025 May 1;43(5):827-840. [Abstract]
Western blot analysis (upper) and summarized data (lower) of p21 expression in MAECs under control condition or treated with 100 nM Ponatinib in the absence or in the presence of 100 nM WM-3835 for 24 h. The data are means ± SEM, n = 6 per group. ∗P < 0.05 versus control; #P < 0.05 versus ponatinib.
WM-3835 purchased from MedChemExpress. Usage Cited in: J Hypertens. 2025 May 1;43(5):827-840. [Abstract]
IL-6 and IL-8 levels were measured in MAECs under control condition or treated with 100 nM Ponatinib in the absence or in the presence of 100 nM WM-3835 for 24 h by PCR. The data are means ± SEM, n = 6 per group. ∗P < 0.05 versus control; #P < 0.05 versus ponatinib.
-
bioRxiv
MYST acetyltransferases are a targetable therapeutic vulnerability in SETBP1-mutant leukemia. [Abstract]2026 Jan 8:2026.01.08.697228. PMID: 41542431 -
-
Res Sq
An EGFR Co-Amplified and De Novo Long Noncoding RNA HELDR Promotes Glioblastoma Malignancy through KAT7-Driven Gene Programs. [Abstract]2025 Jun 24:rs.3.rs-6456987. PMID: 40678238 -
bioRxiv
A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer. [Abstract]2025 Apr 26:2025.04.23.650241. PMID: 40568091
Solvente y solubilidad
DMSO : 175 mg/mL (437.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4974 mL | 12.4869 mL | 24.9738 mL | 62.4344 mL |
| 5 mM | 0.4995 mL | 2.4974 mL | 4.9948 mL | 12.4869 mL | |
| 10 mM | 0.2497 mL | 1.2487 mL | 2.4974 mL | 6.2434 mL | |
| 15 mM | 0.1665 mL | 0.8325 mL | 1.6649 mL | 4.1623 mL | |
| 20 mM | 0.1249 mL | 0.6243 mL | 1.2487 mL | 3.1217 mL | |
| 25 mM | 0.0999 mL | 0.4995 mL | 0.9990 mL | 2.4974 mL | |
| 30 mM | 0.0832 mL | 0.4162 mL | 0.8325 mL | 2.0811 mL | |
| 40 mM | 0.0624 mL | 0.3122 mL | 0.6243 mL | 1.5609 mL | |
| 50 mM | 0.0499 mL | 0.2497 mL | 0.4995 mL | 1.2487 mL | |
| 60 mM | 0.0416 mL | 0.2081 mL | 0.4162 mL | 1.0406 mL | |
| 80 mM | 0.0312 mL | 0.1561 mL | 0.3122 mL | 0.7804 mL | |
| 100 mM | 0.0250 mL | 0.1249 mL | 0.2497 mL | 0.6243 mL |
WM-3835 Related Classifications
HY-134901 Related Classifications
Powered by Bioz